Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bressan, R. A.
Right arrow Articles by Pilowsky, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bressan, R. A.
Right arrow Articles by Pilowsky, L. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 18, No. 1, 124-127 (2004)
DOI: 10.1177/0269881104040251

Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity

Rodrigo A. Bressan

Section of Neurochemical Imaging and Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, London, UK and Departamento de Psiquiatria, Universidade Federal de Sao Paulo, UNIFESP, Sao Paulo, Brazil r.bressan{at}psiquiatria.epm.br

Hugh M. Jones

Section of Neurochemical Imaging and Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, London, UK

Lyn S. Pilowsky

Section of Neurochemical Imaging and Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, London, UK

Evidence suggests atypical antipsychotic treatment is associated with a lower incidence of tardive dyskinesia (TD) than typical antipsychotic drugs, and is a potential antidyskinetic treatment. We present the case of a middle-aged woman never previously exposed to antipsychotic treatment who developed TD after 6 months of olanzapine monotherapy. Substitution of quetiapine for olanzapine alleviated her TD symptoms. The case demonstrates that atypical antipsychotic drugs have different effects in relation to TD. Potential psychopharmacological mechanisms explaining these differences are discussed, highlighting the importance of D2 receptor occupancy by atypical antipsychotic drugs for TD.

Key Words: antipsychotic agents • atypical antipsychotic drugs • clozapine • dopamine • D2 receptors • olanzapine • quetiapine • risperidone • tardive dyskinesia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
H. S. DUGGAL and D. N. MENDHEKAR
Atypical Antipsychotics, Tardive Dyskinesia, and D2 Receptors
Am J Psychiatry, August 1, 2006; 163(8): 1449 - 1450.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
F.-G. B. Pajonk, A. K. Schwertner, and M. A. Seelig
Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series
J Psychopharmacol, January 1, 2006; 20(1): 119 - 124.
[Abstract] [PDF]